Drugs / Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00952822 | Aug 2008 → Oct 2009 | hemophilia A | Baxalta now part of Shire | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2021-02-03 | Takeda | Results Data at EAHAD 2021 Highlight Value of Takeda’s Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused Advancements takeda.com ↗
Seven year AHEAD study data [ABS034] showed that prophylactic antihemophilic factor (recombinant), rAHF (ADVATE), achieved lower annualized bleeding rates (ABRs) and annualized joint bleeding rates (AJBRs) than on-demand treatment in all patients with severe hemophilia A. |
| 2020-06-15 | Takeda | Results Takeda Provides Updates on its Hemophilia Studies at WFH 2020, Reinforcing its Commitment to Putting Patients First and Supporting Personalized Care for People with Bleeding Disorders takeda.com ↗
The update is one of the three abstracts being presented at WFH 2020 from Takeda’s Hematology portfolio and pipeline. |
| 2018-12-01 | Takeda | Results Initial Data from Shire Collaboration Identifies Key Biomarkers That Affect Bleeding Patterns, Response to Treatment for Hemophilia A takeda.com ↗
The study also supports the feasibility of using limited, 2-sample PK profiling to capture accurate PK curves that can then be utilized to guide individualized, PK-guided prophylaxis. |
All press releases naming this drug 4 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00952822 ↗ |
| Known as | Factor VIII | “Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)” NCT00952822 ↗ |
| Modality | Protein / enzyme biologic | “Biological: Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM).” NCT00952822 ↗ |